Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help to predict breast cancer prognosis.
Methods
MMP-2, MMP-14 and TIMP-2 expression has been evaluated by 35S mRNA in situ hybridization on paraffin material of 539 breast cancers without distant metastasis at diagnosis and with a median follow-up of 9.2 years.
Results
MMP-2 and MMP-14 mRNA was detected primarily in reactive stromal cells whereas TIMP-2 mRNA was expressed by both stromal and cancer cells. Of the three molecules, an adjusted Cox model revealed that high MMP-14 mRNA (≥ 10% cells) alone predicted a significantly shorter overall survival (p = 0.031) when adjusted for clinical factors (tumor size and number of involved lymph nodes). Prognostic significance was lost when further adjusted for Her-2/neu and urokinase-type plasminogen activator (p = 0.284). Furthermore, when all three components were analyzed together, the survival was worst for patients with high MMP-2/high MMP-14/low TIMP-2 (5 year survival = 60%) and best with low MMP-2/low MMP-14/high TIMP-2 (5 year survival = 74%), but the difference did not reach statistical significance (p = 0.3285).
Conclusion
Of the MMP-14/TIMP-2/MMP-2 complex, MMP-14 was the factor most significantly associated with the outcome of breast cancer and was an independent factor of poor overall survival when adjusted for clinical prognostic factors, but not for certain ancillary markers.
The online version of this article (doi:10.1186/bcr1503) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BT, JB, CSW, and DT participated in the design of the study. CSW, HL and GB developed and prepared all in situ hybridization analyses. BT and DT interpreted all in situ hybridization slides. JB supervised the statistical analysis, which was carried out by CB. All authors participated to the discussion on the significance of the results, the drafting of the manuscript and approved the final version.
Abkürzungen
bp
base-pair
ECM
extracellular matrix
HSP
heat-shock protein
MMP
matrix metalloproteinase
OS
overall survival
TIMP
tissue inhibitor of metalloproteases
uPA
urokinase-type plasminogen activator.
Introduction
In breast cancer, matrix metalloproteinase (MMP)-2 is a protease produced essentially by stromal cells. In vitro studies have clearly demonstrated that it degrades molecules that are abundant in the extracellular matrix (ECM) [1]. MMP-2 is also one of the major targets of recently developed synthetic MMP inhibitors [2, 3]. However, recent literature demonstrates that the mechanism of action of MMP-2 is complex and that other molecules modulate its activity [4, 5].
MMP-2 is secreted in an inactive pro-enzymatic form and, unlike other MMPs, its activity is modulated by tissue inhibitor of metalloproteases (TIMP)-2 [6] and the membrane type 1 MMP (MMP-14) [7]. Using zymography, breast cancers were found to express higher levels of activated MMP-2 than benign lesions [8, 9] and in vitro studies showed that activated MMP-2 only is associated with an aggressive potential in breast cancer cell lines [10].
Anzeige
Animal studies showed that carcinoma cell lines transfected with MMP-14 produced higher levels of active MMP-2 and developed more lung metastases compared to parent tumor cells [11]. TIMP-2 inhibits most if not all activated MMPs and was shown to form a complex specifically with pro-MMP-2 [12]. However, the role of TIMP-2 is ambiguous since, in addition to its inhibitory effect, it is a main player in the MMP-2 activation cascade [13]. However, clinical studies on breast cancer are rare, limited in size and do not address the potential interaction of all three factors (MMP-2, MMP-14 and TIMP-2).
This prompted us to test the hypothesis that the individual expression or the balance between MMP-2, MMP-14 and TIMP-2 expression may help to predict breast cancer prognosis.
Materials and methods
Population
The patients included in this study had node-positive or node-negative disease proven by histological examination of axillary lymph nodes, but with absence of distant metastases at diagnosis. The surgery for breast carcinoma was performed between 1 January 1980 and 31 December 1986. Clinical information was obtained from the patients' charts by experienced research nurses. The tumor size, and number of examined and positive lymph nodes were obtained from the pathology reports. The histological types along with the histological and nuclear grades were reassessed by one of us (BT). The project has been approved by the Laval University Ethical Review board.
In situ hybridization
MMP-2, MMP-14 and TIMP-2 expression was analyzed by in situ hybridization. The technique used was a modification of the method of Wolf and colleagues [14] as described before [15]. S35 labeled antisense RNA probes were used. Plasmids were kindly provided by the late Prof. Paul Basset, IGBMC, Illkirch, France (MMP-2 and MMP-14) and the late Dr Anna Kossakowska, Calgary, Alberta (TIMP-2). cDNA inserts were prepared from breast cancer cDNA libraries, subcloned in pBluescript II (MMP-2 and MMP-14) and pBS KS- (TIMP-2) vectors and were used as templates for in vitro transcription to generate sense and anti-sense probes. The 2,124 base-pair (bp) MMP-2 cDNA was subcloned in the EcoRI site and extended from nucleotide 26 to 2,150; the 1,159 bp MMP-14 cDNA was subcloned in the EcoR1 site and extended from nucleotide 454 to 1,613; and the 210 bp TIMP-2 cDNA was subcloned in the HindIII/BamH1 site. Reduction of the probe length was achieved by partial alkaline hydrolysis. The quality of RNA preservation has been assessed with the use of antisense RNA probes for β-actin and negative controls were obtained with the use of sense probes. In situ hybridization for MMP-11 and urokinase-type plasminogen activator (uPA) were performed on all cases as previously described [15].
Anzeige
Immunohistochemistry
In addition to in situ hybridization, an immunohistochemical study was performed using the avidin-biotin complex (ABC) method as described before [15]. Studies were performed using primary antibodies to cathepsin D (Novocastra, Newcastle, UK; dilution, 1/200), p53 (Signet Labs, Dedham, MA, USA; ID labs, London, Ontario, Canada; dilution, 1/50), the heat-shock protein of 27 kDa (HSP-27, Hu27, Dr Jacques Landry, Hôtel-Dieu de Québec, Canada; dilution, 1/200), and HER-2/neu (Triton Biosciences, Alameda, CA, USA; dilution, 1/15). For each antibody, positivity was defined by the presence of at least 10% of cells expressing the marker. P53 expression was nuclear, HER-2/neu was membranous and HSP-27 was cytoplasmic.
Flow cytometry
DNA flow cytometric analysis was performed in all cases on formalin fixed-paraffin embedded tissues using the method described by Dressler and colleagues [16]. Ploidy and S-phase fraction were determined on single parameter histograms with the use of ModFit® (Verity Software House Inc., Topsham, ME, USA). Debris were excluded with the use of the 'Single Cut' algorithm. G0, G1 and G2 M were defined from a Gaussian curve while S-phase fraction was evaluated with the trapezoid model. All cases with a coefficient of variation exceeding 8% were excluded; the coefficient of variation averaged 6.1% (range 2.5% to 8.0%).
Hormone receptors
Estrogen and progesterone receptor measurement was obtained from the patient charts. In the early 1980s, analyses were performed using the hydroxylapatite method [17]. Positivity was defined by hormone levels above 10 fmol/mg proteins.
Interpretation
The light microscopic interpretation of in situ hybridization was done by two of us (BT, DT) without knowledge of the clinical information. The scoring was assessed separately on cancer and stromal cells using a semi-quantitative scale similar to that used for immunohistochemistry. For each cell compartment, the percentage of cancer or stromal cells expressing the marker (0%, <10%, 10% to 50%, >50%) was evaluated on the whole tumor surface of one representative section.
Statistical analysis
Distant-metastasis-free and overall survival (OS) curves were obtained for each protease according to Kaplan and Meier [18]. The difference between the curves was assessed using the log-rank test [19]. Correlation between protease expression and other recognized prognostic variables in breast cancer was determined by the Chi-square test [19]. Distant-metastasis-free and OS curves were generated using 10% as the cutoff point between those expressing low (negative) or high (positive) protease levels by stromal cells, as defined before [15, 20]. The Cox proportional hazard model was used to evaluate the relationship between the expression of each protease, or a combination of more than one protease, and recurrence or death, adjusting for other known or suspected prognostic factors [21]. Hazard ratios for the occurrence of distant metastases or death of patients with any of the above combinations were obtained by univariate and multivariate analyses.
Results
In our tumor bank, information for MMP-2 was available from 610 breast cancers, from 544 for MMP-14 and from 549 cases for TIMP-2. Results for all three molecules were available from 539 cases and all analyses have been performed on this group of patients. The patients' ages ranged from 29 to 72 years (average, 57.3). Of these patients, 190 (35.3%) were node-negative, 340 (63.1%) had node invasion, and the node status was unknown in 9 (1.6%). At last follow-up, 258 (47.9%) were alive and the follow-up of surviving patients ranged from 5.2 to 14.6 years (average, 9.5 years); 21 (3.9%) were lost to follow-up.
In this study, stromal cells expressed high MMP-2 (Figure 1a) in 263 (48.8%) cases, high MMP-14 (Figure 1b) in 164 (30.4%) cases and high TIMP-2 (Figure 1c) in 200 (37.1%) cases. Furthermore, high TIMP-2 expression by cancer cells (Figure 1d) was present in 225 (41.7%) cases while cancer cells expressed MMP-14 in 4 (0.7%) cases and none expressed MMP-2.
Figure 1
Expression of matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 in stromal and cancer cells. (a) MMP-2 expression by stromal cells (in situ hybridization, × 200); (b) MMP-14 expression by stromal cells (in situ hybridization, × 200); (c) TIMP-2 expression by stromal cells (in situ hybridization, × 200); (d) TIMP-2 expression by cancer cells (in situ hybridization, × 200). Scale bar = 200 microns. C, cancer cells; S, stromal cells.
×
MMP-14 expression by stromal cells was significantly associated with a younger age, lymph node involvement, a ductal histology, HER-2/neu overexpression, and cathepsin D, MMP-11 (stromelysin-3) and uPA expression by stromal cells (Table 1). MMP-2 expression by stromal cells was associated with lymph node involvement, ductal histology, HER-2/neu and HSP-27 overexpression as well as cathepsin D, MMP-11 and uPA expression by stromal cells. TIMP-2 expression by stromal cells was associated with a ductal histology, and expression of HSP-27 and uPA. TIMP-2 expression by cancer cells was associated with peritumoral lymphovascular invasion, and expression of HSP-27, cathepsin D and uPA by stromal cells.
Table 1
Association of high protease expression by stromal cells with other prognostic factors
Parameter
Cases
MMP-14
MMP-2
TIMP-2: stromal cells
TIMP-2: cancer cells
Number
Percentage Pos
p value
Number
Pecentage Pos
p value
Number
Percentage Pos
p value
Number
Percentage Pos
p value
Age years
<50
160
59
36.9
0.034
85
53.1
0.19
58
36.3
0.79
59
36.9
0.14
≥50
379
105
27.7
178
47.0
142
37.5
166
43.8
Tumor size cm
<3
297
93
31.3
0.98
146
49.2
0.65
118
39.7
0.14
122
41.1
0.83
≥3
207
65
31.4
106
51.2
69
33.3
87
42.0
Involved lymph nodes
0
190
46
24.2
81
42.6
71
37.4
80
42.1
1 to 3
166
61
36.7
0.036
93
56.0
0.041
69
41.6
0.29
75
45.2
0.52
>3
174
54
31.0
84
48.3
58
33.3
68
39.1
Peritumoral lymphovascular invasion
Yes
143
50
35.0
0.15
76
53.1
0.097
50
35.0
0.15
64
44.8
0.027
No
75
19
25.3
31
41.3
19
25.3
22
29.3
Histological grade
I
54
18
33.3
25
46.3
19
35.2
23
42.6
II
277
81
29.2
0.69
133
48.0
0.83
109
39.4
0.59
119
42.9
0.82
III
197
64
32.5
99
50.3
69
35.0
79
40.1
Nuclear grade
I
94
20
21.3
40
42.6
39
41.5
42
44.7
II
307
98
31.9
0.066
158
51.5
0.27
105
34.2
0.22
128
41.7
0.79
III
127
45
35.4
59
46.5
53
41.7
51
40.2
Histological type
Invasive ductal carcinoma
470
156
33.2
0.0006
238
50.6
0.021
164
34.9
0.003
28
43.1
0.83
Others
65
8
12.3
23
35.4
35
53.8
196
41.7
DNA ploidy
Diploid
143
37
25.9
0.09
64
44.8
0.18
58
40.6
0.59
60
42.0
0.99
Non-diploid
332
112
33.7
171
51.5
126
38.0
139
41.9
Estrogen receptors
Negative
143
53
37.1
0.055
76
53.1
0.22
59
41.3
0.25
61
42.7
0.89
Positive
374
106
28.3
176
47.1
134
35.8
157
42.0
Progesterone receptors
Negative
219
74
33.8
0.21
109
49.8
0.72
88
40.2
0.26
95
43.4
0.60
Positive
297
85
28.6
143
48.1
105
35.4
122
41.1
HER-2/neu expression
Negative
437
121
27.7
0.0042
204
46.7
0.042
158
36.2
0.34
179
41.0
0.45
Positive
102
43
42.2
59
57.8
42
41.2
46
45.1
p53
Negative
374
107
28.6
0.12
186
49.7
0.53
132
35.3
0.24
149
39.8
0.30
Positive
152
54
35.5
71
46.7
62
40.8
68
44.7
HSP-27
Negative
204
61
29.9
0.097
97
47.5
0.02
63
30.9
0.0024
70
34.3
0.0003
Positive
157
60
38.2
94
59.9
73
46.5
84
53.5
Cathepsin D cancer cells
Negative
324
94
29.0
0.29
151
46.6
0.21
111
34.3
0.071
127
39.2
0.102
Positive
207
69
33.3
87
52.2
87
42.0
96
46.4
Cathepsin D stromal cells
Negative
303
78
25.7
0.0035
130
42.9
0.0013
106
35.0
0.21
116
38.3
0.047
Positive
226
85
37.6
129
57.1
91
40.3
106
46.9
MMP-11
Negative
215
32
14.9
<0.0001
65
30.2
<0.0001
76
35.3
0.46
93
43.3
0.60
Positive
322
132
41.0
198
61.5
124
38.5
132
41.0
MMP-2
Negative
276
41
14.9
<0.0001
-
-
89
32.2
0.017
110
39.9
0.36
Positive
263
123
46.8
-
-
111
42.2
115
43.7
uPA
Negative
374
81
21.7
<0.0001
147
39.3
<0.0001
127
34.0
0.016
143
38.2
0.017
Positive
160
81
50.6
115
71.9
72
45.4
79
49.4
HSP, heat-shock protein; MMP, matrix metalloproteinase; Pos, positive; TIMP, tissue inhibitor of metalloproteases; uPA, urokinase-type plasminogen activator.
Anzeige
Figure 2 shows the OS curves for each of the three proteases. MMP-2 and MMP-14 expression by cancer cells was not evaluated because too few cases expressed those markers. No difference in OS was found between high and low MMP-2 and between high and low stromal and cancer TIMP-2 expression. However, high MMP-14 expression by stromal cells predicted a shorter survival (p = 0.05). In fact, the 5 year survival reached 72.2% for patients whose tumors had low MMP-14 levels as opposed to 64.6% for those with high MMP-14 levels. By multivariate analysis, using the Cox model adjusting for tumor size and number of involved lymph nodes, high MMP-14 expression was clearly a significant factor of poor survival (Table 2). The statistical significance was lost when HER-2/neu and uPA were included in the model. A trend was found for the association of MMP-14 expression and metastasis-free survival (p = 0.08). Indeed, the 5 year metastasis-free survival was 64.0% for patients with low MMP-14 as opposed to 54.3% for those with high MMP-14.
Figure 2
Overall survival for matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 expression by stromal and cancer cells. Overall survival curves for: (a) matrix metalloproteinase (MMP)-2 expressed by stromal cells; (b) MMP-14 expressed by stromal cells; (c) tissue inhibitor of metalloproteases (TIMP)-2 expressed by stromal cells; and (d) TIMP-2 expressed by cancer cells (p values obtained by the log-rank test).
×
Table 2
Hazard ratios for MMP-14, MMP-2, TIMP-2 and combination of MMP-14 MMP-2 TIMP-2 on breast cancer overall survival
Univariate
Multivariatea
Multivariateb
HR
95% CI
p value
HR
95% CI
p value
HR
95% CI
p value
MMP-14
1.31
0.99–1.72
0.05
1.36
1.03–1.81
0.031
1.18
0.87–1.59
0.28
MMP-2
1.14
0.88–1.47
0.33
1.14
0.87–1.49
0.34
0.98
0.73–1.31
0.87
TIMP-2: stromal cells
0.91
0.69–1.19
0.51
1.04
0.78–1.38
0.79
0.89
0.66–1.19
0.43
TIMP-2: cancer cells
1.07
0.83–1.39
0.61
1.09
0.83–1.43
0.53
1.02
0.77–1.34
0.91
MMP-14-/MMP-2-/TIMP-2+c
1.0
1.0
MMP-14+/MMP-2+/TIMP-2-
1.46
0.89–2.38
0.13
1.29
0.77–2.16
0.33
Other categories
1.11
0.76–1.63
0.59
1.03
0.68–1.55
0.90
aCox model adjusting for tumor size and number of involved lymph nodes. bCox model adjusting for tumor size, number of involved lymph nodes, HER-2/neu and urokinase plasminogen activator. cTIMP-2 by stromal cells. CI, confidence interval; HR, hazard ratio; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteases.
Figure 3 shows the overall survival curve considering the balance between MMP-2, MMP-14 and TIMP-2. Of the different combinations, OS was worst for those patients with high stromal MMP-2/high stromal MMP-14/low stromal TIMP-2 (60.3% survival at 5 years) and best with low stromal MMP-2/low stromal MMP-14/high stromal TIMP-2 (74.4% survival at 5 years). This difference did not, however, reach significance (p = 0.25).
Figure 3
Overall survival curves for: matrix metalloproteinase (MMP)-2, MMP-14 and stromal tissue inhibitor of metalloproteases (TIMP)-2 (p values obtained by the log-rank test).
×
Discussion
This study confirms the complexity of the role of proteases on breast cancer prognosis. However, the prognostic influence of MMP-2 expression is not clear in the literature. Talvensaari-Mattila and colleagues [22], Sivula and colleagues [23] and Pacheco and colleagues [24] are among the few investigators who demonstrated a significant association between high MMP-2 mRNA or protein expression levels and a poor outcome. In our study of close to 600 cases, MMP-2 overexpression predicted a 15% greater risk of recurrence [15] but the association of MMP-2 expression with prognosis was not statistically significant. Other studies have failed to relate MMP-2 expression to a poorer prognosis [2, 15, 25]. These data are consistent with the complexity of the biology of MMP-2. In our study, they may also be explained in part by the fact that in situ hybridization cannot differentiate between the active and inactive forms.
In our study, when each factor was taken separately, and after adjustment for clinical prognostic factors, only MMP-14 was a significant factor of survival, suggesting that MMP-14 may be one of the key steps in tumor invasion and metastasis. However, the prognostic significance of MMP-14 was not independent of HER-2/neu and uPA. This finding can be explained by the strong regulatory interaction between HER-2/neu, uPA and MMPs [26]. Indeed, HER-2/neu was found to induce uPA expression and to directly up-regulate MMP expression via transcription factor-binding sites [26].
Anzeige
However, the association of MMP-14 but not MMP-2 expression with survival may be explained by the fact that MMP-14 has many substrates other than MMP-2. Indeed, in vitro and clinical studies support the major role played by MMP-14 on ECM remodeling. MMP-14 acts either directly by degrading ECM components such as type III collagen or indirectly by activating pro-MMP-2 and also by inducing highly vascularized tumors through vascular endothelial growth factor (VEGF) up-regulation [27‐30]. MMP-14 also induces functional activation of the integrin αVβ3, which binds to MMP-2 and increases vitronectin-mediated adhesion and migration of MCF7 cells [31]. Among prior clinical studies, high MMP-14 mRNA expression was an independent factor of both tumor invasion and lymph node metastasis in carcinoma of stomach [32], lung [33] and cervix [34]. In breast cancer, highest expression of MMP-14 by RT-PCR was found in cases with lymph node metastases [35, 36], poor clinical stage and larger tumor size [36].
In our study, MMP-14 mRNA was located in reactive stromal cells close to cancer cells. This is consistent with data from the literature [37] that identified MMP-14 mRNA within myofibroblasts [38]. However, the location of MMP-14 in breast tissue is debated and others found MMP-14 mRNA in cancer cells [39]. Using immunohistochemistry, MMP-14 was located within either stromal and/or cancer cells [40‐43].
In our study, TIMP-2 did not provide independent prognostic information. In the literature on breast cancer, the role of TIMP-2 was controversial. This may explain contradictory results in which patients with higher TIMP-2 expression either experienced low cancer recurrence/progression [44, 45] or a poor prognosis [25, 46‐49], emphasizing the overall activating or inhibitory role of TIMP-2. These contradictory findings may be explained by the versatile role of TIMP-2 [12]. Indeed, TIMP-2 increases growth rates of murine, bovine and human cells [50], but also inhibits tumor growth and angiogenesis in melanoma B16F10 cells [51], attenuates migration of MDA-MB23 breast cancer cells through a bone marrow fibroblast monolayer [52] and abolishes the tumor-promoting effect of fibroblasts on MCF7 cells injected with matrigel in nude mice [53].
The relationship of survival with the combination of MMP-2, MMP-14 and TIMP-2, although not statistically significant, showed that survival was worst for those patients with high MMP-2/high MMP-14/low TIMP-2 and best with low MMP-2/low MMP-14/high TIMP-2. This lack of statistical significance may be explained by the sample size, which may be too small to reach significance, or by the versatile role of TIMP-2, which may be either a favorable or an unfavorable factor. Different combinations of proteases and protease inhibitors or activators have been investigated in the literature but clinical studies are limited and involve few patients. Clinical studies suggest that TIMP-2, or the ratio of MMP-2 and TIMP-2 expression, may play a critical role on cancer progression. For example, higher MMP-2/TIMP-2 ratios were associated with recurrences in patients with bladder [54] or uterine cervix [55] cancer. In a study on 14 patients, Onisto and colleagues [56] report that a high MMP-2/TIMP-2 ratio correlated with lymph node metastases in breast cancer while it predicted a better outcome in another study [25].
Anzeige
Conclusion
Our data show that, of the three proteases studied, MMP-14 was most strongly associated with breast cancer prognosis but was not independent of HER-2/neu or uPA, which may limit its usefulness as a prognostic marker. When all three proteases are studied in combination, a tendency was found for tumors with high MMP-2, high MMP-14 and low TIMP-2 expression to predict a poor prognosis but the results did not reach significance.
Acknowledgements
Sources of support: project supported by the Cancer Research Society Inc. Data base has been raised through a grant from the National Cancer Institute of Canada with funds from the Canadian Cancer Society, the Canadian Breast Cancer Foundation and a joint program from the 'Fonds de la Recherche en Santé du Québec' and Hydro-Québec. Dr Têtu was recipient of a research clinical scholarship of the 'Fonds de la Recherche en Santé du Québec' when he completed this project.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BT, JB, CSW, and DT participated in the design of the study. CSW, HL and GB developed and prepared all in situ hybridization analyses. BT and DT interpreted all in situ hybridization slides. JB supervised the statistical analysis, which was carried out by CB. All authors participated to the discussion on the significance of the results, the drafting of the manuscript and approved the final version.
